PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases

by Petra Hillmann, Doriano Fabbro
Published 2019-11-01

Notch Inhibition in Cancer: Challenges and Opportunities

by Doriano Fabbro, Michael Bauer, Maximilien Murone, Rajwinder Lehal
Published 2020-10-01

Correction: Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis

by Nataliya Kotelevets, Doriano Fabbro, Andrea Huwiler, Uwe Zangemeister-Wittke
Published 2013-01-01

Correction: Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis.

by Nataliya Kotelevets, Doriano Fabbro, Andrea Huwiler, Uwe Zangemeister-Wittke
Published 2013-01-01

Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis.

by Nataliya Kotelevets, Doriano Fabbro, Andrea Huwiler, Uwe Zangemeister-Wittke
Published 2012-01-01

Phosphorylation, Signaling, and Cancer: Targets and Targeting

by Sandra Marmiroli, Doriano Fabbro, Yoshihiko Miyata, Mariaelena Pierobon, Maria Ruzzene
Published 2015-01-01

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

by Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, Emanuele Zucca, Anastasios Stathis, Matthias P. Wymann, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni
Published 2019-06-01

Author Correction: Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinase

by Naomi N. K. Kreamer, Rajiv Chopra, Ruth E. Caughlan, Doriano Fabbro, Eric Fang, Patricia Gee, Ian Hunt, Min Li, Barbara C. Leon, Lionel Muller, Brian Vash, Angela L. Woods, Travis Stams, Charles R. Dean, Tsuyoshi Uehara
Published 2018-10-01

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

by Thomas Bohnacker, Andrea E. Prota, Florent Beaufils, John E. Burke, Anna Melone, Alison J. Inglis, Denise Rageot, Alexander M. Sele, Vladimir Cmiljanovic, Natasa Cmiljanovic, Katja Bargsten, Amol Aher, Anna Akhmanova, J. Fernando Díaz, Doriano Fabbro, Marketa Zvelebil, Roger L. Williams, Michel O. Steinmetz, Matthias P. Wymann
Published 2017-03-01